BVS
Bioventus Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+26/100
Last price
13.10
▼ 0.42 (3.11%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
13.52
Day high
13.62
Day low
13.07
Volume
295.45K
Market cap
$894.80M
P/E (TTM)
17.24
52W range
6.37 – 15.89
Trailing performance
Returnvs SPY
1W
-6.43%
-8.4%
1M
-6.89%
-8.0%
3M
+8.18%
+3.7%
6M
+48.19%
+30.0%
YTD
+76.08%
+61.8%
1Y
+86.61%
+70.2%
3Y
+296.97%
+214.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.96M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 2, 26 | MCMURRY-HEATH MICHELLE Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | NOHRA GUY P Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | SUTTER MARTIN P Director and Beneficial Owner of more than 10% of a Class of Security |
— | 32.28K | — | Direct |
| Jun 2, 26 | NEELS GUIDO J Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | BARTHOLDSON JOHN A Director and Beneficial Owner of more than 10% of a Class of Security |
— | 32.28K | — | Direct |
| Jun 2, 26 | STALNECKER SUSAN M Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | BEYER PATRICK J Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | LADONE MARY KAY Director |
— | 32.28K | — | Direct |
| Jun 2, 26 | HAWKINS WILLIAM A III Director |
— | 39.79K | — | Direct |
| Jun 2, 26 | COWDY PHILIP G Director |
— | 32.28K | — | Direct |
| Apr 10, 26 | SINGLETON MARK LEONARD Chief Financial Officer |
— | 13.00K | — | Direct |
| Apr 10, 26 | CHURCH KATRINA J Officer |
— | 4.30K | — | Direct |
| Apr 10, 26 | D'ADAMIO ANTHONY General Counsel |
— | 9.93K | — | Direct |
| Mar 20, 26 | SINGLETON MARK LEONARD Chief Financial Officer |
— | 18.63K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARTHOLDSON JOHN A |
Director and Beneficial Owner of more than 10% of a Class of Security | 7.05M | Conversion of Exercise of derivative security |
CLAYPOOLE ROBERT E. |
Chief Executive Officer | 135.94K | Conversion of Exercise of derivative security |
D'ADAMIO ANTHONY |
General Counsel | 153.66K | Conversion of Exercise of derivative security |
HAWKINS WILLIAM A III |
Director | 297.64K | Conversion of Exercise of derivative security |
LADONE MARY KAY |
Director | 111.26K | Conversion of Exercise of derivative security |
NEELS GUIDO J |
Director | 117.52K | Conversion of Exercise of derivative security |
NOHRA GUY P |
Director | 148.89K | Conversion of Exercise of derivative security |
SINGLETON MARK LEONARD |
Chief Financial Officer | 177.33K | Conversion of Exercise of derivative security |
STALNECKER SUSAN M |
Director | 138.24K | Conversion of Exercise of derivative security |
SUTTER MARTIN P |
Director and Beneficial Owner of more than 10% of a Class of Security | 13.14M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$894.80M
Enterprise value$1.18B
Revenue (TTM)$581.85M
Gross profit$399.45M
EBITDA$80.14M
Net income$54.46M
EPS (TTM)$0.76
Free cash flow$67.76M
Total cash$30.39M
Total debt$263.75M
Book value / share$3.35
Shares outstanding68.31M
Float34.30M
Short % of float6.25%
Dividend yield0.00%
Beta (5Y)0.64
Valuation & profitability ratios
Trailing P/E17.24
Forward P/E14.24
PEG ratio1.53
Price / sales—
Price / book3.91
EV / revenue2.02
EV / EBITDA14.69
Gross margin68.65%
Operating margin12.23%
Profit margin9.36%
Return on equity25.68%
Return on assets5.49%
Debt / equity95.08
Current ratio1.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $568.09M | $573.28M | $512.35M | $512.12M | -0.9% |
| Operating revenue | $568.09M | $573.28M | $512.35M | $512.12M | -0.9% |
| Cost of revenue | $179.93M | $185.05M | $184.15M | $181.04M | -2.8% |
| Gross profit | $388.16M | $388.23M | $328.19M | $331.08M | -0.0% |
| Research & development | $12.11M | $13.95M | $13.45M | $23.85M | -13.2% |
| Selling, general & admin | $314.03M | $343.80M | $303.88M | $332.13M | -8.7% |
| Total operating expense | $331.87M | $365.40M | $326.17M | $365.74M | -9.2% |
| Operating income | $56.29M | $22.82M | $2.03M | -$34.66M | +146.6% |
| Net interest income | -$26.49M | -$38.79M | -$40.68M | -$12.02M | +31.7% |
| Pre-tax income | $25.71M | -$52.34M | -$121.11M | -$189.03M | +149.1% |
| Tax provision | -$1.56M | -$5.29M | $85.00K | -$44.37M | +70.4% |
| Net income | $22.73M | -$36.13M | -$156.23M | -$158.70M | +162.9% |
| Net income to common | $22.73M | -$36.13M | -$156.23M | -$158.70M | +162.9% |
| Basic EPS | 0.34 | -0.56 | -2.49 | -2.59 | +160.7% |
| Diluted EPS | 0.33 | -0.56 | -2.49 | -2.59 | +158.9% |
| EBIT | $52.20M | -$13.55M | -$80.44M | -$177.00M | +485.2% |
| EBITDA | $99.21M | $36.01M | -$23.07M | -$121.61M | +175.5% |
| Basic shares | 66.62M | 64.55M | 62.65M | 61.39M | +3.2% |
| Diluted shares | 68.91M | 64.55M | 62.65M | 61.39M | +6.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $51.24M | $41.58M | $36.96M | $30.19M | +23.2% |
| Cash & short-term investments | $51.24M | $41.58M | $36.96M | $30.19M | +23.2% |
| Accounts receivable | $128.30M | $127.39M | $122.79M | $136.29M | +0.7% |
| Inventory | $82.24M | $92.47M | $91.33M | $84.77M | -11.1% |
| Total current assets | $272.84M | $275.61M | $268.00M | $272.57M | -1.0% |
| Property, plant & equipment | $27.02M | $33.52M | $49.96M | $44.15M | -19.4% |
| Goodwill & intangibles | $375.88M | $412.19M | $489.81M | $647.31M | -8.8% |
| Total assets | $683.56M | $727.96M | $810.91M | $1.37B | -6.1% |
| Total current liabilities | $160.38M | $210.40M | $175.50M | $304.02M | -23.8% |
| Current debt | $15.00M | $27.34M | $27.85M | $33.06M | -45.1% |
| Long-term debt | $278.95M | $308.29M | $367.00M | $385.01M | -9.5% |
| Total debt | $293.95M | $335.63M | $394.85M | $418.07M | -12.4% |
| Total liabilities | $455.11M | $542.35M | $589.79M | $960.43M | -16.1% |
| Retained earnings | -$334.93M | -$357.66M | -$321.54M | -$165.31M | +6.4% |
| Shareholder equity | $184.10M | $147.94M | $173.59M | $325.24M | +24.4% |
| Working capital | $112.46M | $65.21M | $92.50M | -$31.44M | +72.5% |
| Net tangible assets | -$191.78M | -$264.25M | -$316.22M | -$322.07M | +27.4% |
| Shares issued | 67.10M | 65.76M | 63.27M | 62.06M | +2.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $27.27M | -$47.05M | -$121.20M | -$144.65M | — | +158.0% |
| Depreciation & amortisation | $47.01M | $49.55M | $57.37M | $55.40M | — | -5.1% |
| Stock-based compensation | $12.67M | $13.27M | $2.72M | $17.59M | — | -4.5% |
| Change in working capital | -$13.84M | -$11.78M | -$3.18M | -$29.73M | — | -17.5% |
| Operating cash flow | $74.67M | $38.80M | $15.34M | -$13.54M | — | +92.5% |
| Capital expenditure | -$2.56M | -$1.01M | -$7.36M | -$1.48M | — | -154.7% |
| Investing cash flow | -$3.25M | $22.96M | $15.81M | -$116.44M | — | -114.1% |
| Dividends paid | — | — | — | $0 | -$367.00K | — |
| Financing cash flow | -$62.14M | -$54.58M | -$26.65M | $62.08M | — | -13.9% |
| Free cash flow | $72.11M | $37.79M | $7.98M | -$15.02M | — | +90.8% |
| End cash position | $51.24M | $41.58M | $36.96M | $31.84M | — | +23.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $153.21M | $132.09M | $157.90M | $138.65M | $147.66M | +16.0% |
| Operating revenue | $153.21M | $132.09M | $157.90M | $138.65M | $147.66M | +16.0% |
| Cost of revenue | $47.54M | $41.32M | $49.12M | $44.42M | $45.57M | +15.1% |
| Gross profit | $105.67M | $90.77M | $108.78M | $94.23M | $102.09M | +16.4% |
| Research & development | $3.17M | $2.47M | $3.01M | $2.92M | $3.17M | +28.6% |
| Selling, general & admin | $82.74M | $78.33M | $82.76M | $78.66M | $79.11M | +5.6% |
| Total operating expense | $86.95M | $81.90M | $87.06M | $82.98M | $83.72M | +6.2% |
| Operating income | $18.71M | $8.87M | $21.72M | $11.25M | $18.37M | +111.0% |
| Net interest income | -$4.07M | -$4.33M | -$5.31M | -$6.18M | -$7.49M | +6.0% |
| Pre-tax income | $15.31M | $4.52M | $14.14M | $4.67M | $10.31M | +238.9% |
| Tax provision | -$20.90M | $571.00K | -$3.17M | $664.00K | $1.04M | -3,759.7% |
| Net income | $33.44M | $3.11M | $14.76M | $3.15M | $7.46M | +974.2% |
| Net income to common | $33.44M | $3.11M | $14.76M | $3.15M | $7.46M | +974.2% |
| Basic EPS | 0.49 | 0.05 | 0.22 | 0.05 | 0.11 | +880.0% |
| Diluted EPS | 0.47 | 0.04 | 0.21 | 0.05 | 0.11 | +1,075.0% |
| EBIT | $19.38M | $8.84M | $19.45M | $10.85M | $17.81M | +119.1% |
| EBITDA | $30.32M | $20.05M | $31.14M | $22.25M | $29.86M | +51.2% |
| Basic shares | 67.87M | 67.30M | 67.02M | 66.92M | 66.50M | +0.9% |
| Diluted shares | 70.84M | 70.01M | 69.26M | 68.84M | 68.54M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.46M | $35.85M | $51.24M | $42.16M | $32.91M | -17.8% |
| Cash & short-term investments | $29.46M | $35.85M | $51.24M | $42.16M | $32.91M | -17.8% |
| Accounts receivable | $138.41M | $120.53M | $128.30M | $130.40M | $132.37M | +14.8% |
| Inventory | $79.81M | $83.19M | $82.24M | $96.27M | $96.47M | -4.1% |
| Total current assets | $257.53M | $249.81M | $272.84M | $280.90M | $275.20M | +3.1% |
| Property, plant & equipment | $24.75M | $25.98M | $27.02M | $28.81M | $30.74M | -4.7% |
| Goodwill & intangibles | $358.51M | $367.12M | $375.88M | $384.86M | $394.42M | -2.3% |
| Total assets | $673.35M | $650.54M | $683.56M | $701.59M | $706.79M | +3.5% |
| Total current liabilities | $152.45M | $148.09M | $160.38M | $161.75M | $185.68M | +2.9% |
| Current debt | $18.75M | $18.75M | $15.00M | $11.25M | $43.36M | 0.0% |
| Long-term debt | $229.70M | $253.33M | $278.95M | $311.33M | $297.88M | -9.3% |
| Total debt | $248.45M | $272.08M | $293.95M | $322.58M | $341.24M | -8.7% |
| Total liabilities | $395.93M | $416.27M | $455.11M | $494.34M | $505.49M | -4.9% |
| Retained earnings | -$298.38M | -$331.82M | -$334.93M | -$349.68M | -$352.84M | +10.1% |
| Shareholder equity | $228.31M | $188.90M | $184.10M | $166.10M | $161.24M | +20.9% |
| Working capital | $105.08M | $101.72M | $112.46M | $119.15M | $89.52M | +3.3% |
| Net tangible assets | -$130.20M | -$178.22M | -$191.78M | -$218.76M | -$233.17M | +26.9% |
| Shares issued | 68.21M | 67.64M | 67.10M | 66.97M | 66.89M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $36.20M | $3.95M | $17.32M | $4.01M | $9.27M | +817.5% |
| Depreciation & amortisation | $10.95M | $11.21M | $11.69M | $11.40M | $12.05M | -2.3% |
| Stock-based compensation | $5.04M | $3.26M | $3.44M | $3.18M | $3.64M | +54.4% |
| Change in working capital | -$10.17M | -$10.18M | $6.21M | $10.68M | $477.00K | +0.1% |
| Operating cash flow | $19.87M | $8.93M | $37.97M | $30.10M | $25.94M | +122.4% |
| Capital expenditure | -$960.00K | -$574.00K | -$580.00K | -$473.00K | -$683.00K | -67.2% |
| Investing cash flow | -$2.46M | -$574.00K | -$580.00K | -$473.00K | -$1.37M | -328.6% |
| Financing cash flow | -$23.43M | -$23.14M | -$28.45M | -$19.98M | -$14.66M | -1.2% |
| Free cash flow | $18.91M | $8.36M | $37.39M | $29.63M | $25.25M | +126.2% |
| End cash position | $29.46M | $35.85M | $51.24M | $42.16M | $32.91M | -17.8% |
Options analytics
Put / call volume
2.21
Put-heavy session
Put / call open interest
0.61
Positioning, not flow
Max pain
5.00
-61.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-18.7%
Calls bid over puts
Call volume
29
Contracts, this expiry
Put volume
64
Contracts, this expiry
Heaviest call OI
5.00
57 contracts
Heaviest put OI
7.50
37 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.22 | 0.22 | +0.9% |
| Mar 2026 | 0.07 | 0.15 | +120.6% |
| Dec 2025 | 0.22 | 0.24 | +10.8% |
| Sep 2025 | 0.12 | 0.15 | +30.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.16 | 5 | $149.52M | +7.8% |
| Next quarter | 0.25 | 5 | $169.96M | +7.6% |
| Current year | 0.78 | 5 | $604.78M | +6.5% |
| Next year | 0.92 | 5 | $645.57M | +6.7% |
Analyst targets & ownership
Mean target$17.60
High target$19.00
Low target$15.00
Implied upside34.35%
Analyst count5
ConsensusNONE
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders11.65%
Held by institutions84.69%
Institutions holding218
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.58
-3.53% from price
SMA 20
13.37
-1.99% from price
SMA 50
13.71
-4.43% from price
SMA 100
11.91
+9.98% from price
SMA 200
10.34
+26.75% from price
EMA 12
13.46
-2.65% from price
EMA 26
13.48
-2.84% from price
EMA 50
13.20
-0.73% from price
RSI (14)
44.6
Neutral
MACD (12,26,9)
-0.03
Hist -0.04
ATR (14)
0.49
3.74% of price
Realised vol 30D
34.5%
Annualised
Bollinger upper
14.10
20, 2σ
Bollinger lower
12.63
20, 2σ
50 / 200 cross
Golden
13.71 vs 10.34
Trend bias
Above 200
+26.75%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
34.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.5%
Peak to trough
Max drawdown 5Y
-94.5%
Peak to trough
ATR 14
0.49
3.74% of price
Beta (reported)
0.64
5Y monthly, from filing
Short interest
Shares short
2.93M
Prior 2.33M
Change vs prior
+25.5%
Shorts adding
% of float
6.25%
Normal
% of shares out
4.29%
Against total outstanding
Days to cover
5.4
Crowded exit
Float
34.30M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jun 30, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Jun 16, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 22, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Mar 6, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Mar 6, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Feb 9, 26 | Barrington Research | INITIATED | — | Outperform |
| Jul 7, 25 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Mar 17, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 17, 24 | JP Morgan | UPGRADE | Underweight | Neutral |
| Nov 6, 24 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-04
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-06
Annual Report to Shareholders
ARS · 2026-04-22
Offering Registrations
S-8 · 2026-03-05
Corporate Changes & Voting Matters
8-K · 2025-11-17
Headlines
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Zacks · 44d ago
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
Zacks · 48d ago
Bioventus (BVS) Q2 2026 Earnings Call Transcript
Motley Fool · 55d ago
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
Simply Wall St. · 58d ago
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
Simply Wall St. · 58d ago
Is Bioventus (BVS) Stock Undervalued Right Now?
Zacks · 61d ago
Barrington Adjusts Price Target on Bioventus to $18 From $14, Maintains Outperform Rating
MT Newswires · 62d ago
Bioventus Inc. Q2 2026 Earnings Call Summary
Moby · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.